Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03652077 · ClinicalTrials.gov registry record · Phase 1
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
A Phase 1 study of Melanoma and Gastric Cancer, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 4
- Study locations
NCT03652077 is a Phase 1 study of Melanoma and Gastric Cancer that has completed, run by Incyte Corporation. The registered enrollment target is 40 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (94% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT03652077, a Phase 1 study of Melanoma and Gastric Cancer, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with select advanced malignancies.
Conditions Studied
Interventions
- DRUG INCAGN02390
Study Locations (4)
California
- The Angeles Clinical and Research Institute - Los Angeles
Mississippi
- University of Mississippi - Jackson
New Jersey
- Hackensack Medical Center - Hackensack
North Carolina
- Carolina BioOncology - Huntsville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2018-09-24 |
| Est. Completion | 2021-08-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03652077
The ClinicalTrials.gov registry entry for NCT03652077 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (94% lower). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Melanoma appearing as the primary indexed condition, and to 1 intervention - of which INCAGN02390 is the first listed.
NCT03652077 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Mississippi, New Jersey.
Frequently Asked Questions
What is clinical trial NCT03652077 about?
NCT03652077 is a clinical study titled "A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies". The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with select advanced malignancies.
What is the current status of trial NCT03652077?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2018-09-24. Estimated completion is 2021-08-18.
What conditions does trial NCT03652077 study?
This clinical trial studies the following conditions: Melanoma, Gastric Cancer, Cervical Cancer, Hepatocellular Carcinoma, Esophageal Cancer.
What interventions are being tested in trial NCT03652077?
The interventions under investigation include: INCAGN02390 (DRUG).
Who is sponsoring clinical trial NCT03652077?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03652077 being conducted?
This trial has 4 study locations across California, Mississippi, New Jersey, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.